Published in Front Biosci on September 01, 2007
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer | NCT00514072
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate (2010) 2.22
Castration eliminates conspecific aggression in group-housed CD1 male surveillance mice (Mus musculus). J Am Assoc Lab Anim Sci (2012) 1.72
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res (2013) 1.15
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol (2010) 1.08
Current status of immunological therapies for prostate cancer. Curr Opin Urol (2010) 1.06
Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther (2009) 1.05
Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging (2010) 0.96
Immunotherapy for prostate cancer: an emerging treatment modality. Urol Clin North Am (2010) 0.94
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2011) 0.94
Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Psychooncology (2014) 0.94
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother (2011) 0.93
A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res (2013) 0.93
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol (2012) 0.92
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget (2015) 0.92
In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res (2010) 0.91
Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91
Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev (2014) 0.90
Update on prostate cancer vaccines. Cancer J (2011) 0.88
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl (2011) 0.87
Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines (2014) 0.86
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis (2015) 0.86
Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol (2013) 0.86
Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther (2010) 0.85
Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine (2011) 0.84
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84
Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl (2014) 0.84
Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: results from an Australian population-based case-control study. Br J Cancer (2010) 0.84
The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer (2010) 0.83
Concept and viability of androgen annihilation for advanced prostate cancer. Cancer (2014) 0.82
Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol (2012) 0.81
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Rev Vaccines (2011) 0.80
Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2015) 0.80
Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. Adv Ther (2013) 0.79
Roles of prohibitin in growth control and tumor suppression in human cancers. Transl Oncogenomics (2008) 0.78
Androgen activity and markers of inflammation among men in NHANES III. Am J Hum Biol (2013) 0.78
Prediction of treatment efficacy for prostate cancer using a mathematical model. Sci Rep (2016) 0.78
Therapeutic cancer vaccines: the latest advancement in targeted therapy. Am J Ther (2012) 0.78
Opposing effects of androgen ablation on immune function in prostate cancer. Oncoimmunology (2012) 0.77
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. Immunotherapy (2011) 0.75
Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer. Am J Epidemiol (2016) 0.75
Current perspectives in prostate cancer vaccines. Anticancer Agents Med Chem (2009) 0.75
Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder. PLoS One (2017) 0.75
Hormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction. Indian J Urol (2014) 0.75
Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer. Cancers (Basel) (2012) 0.75
Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? Cancer Med (2013) 0.75
Sipuleucel-T: immunotherapy for advanced prostate cancer. Open Access J Urol (2011) 0.75
A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev (2017) 0.75
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Cancer vaccines: moving beyond current paradigms. Clin Cancer Res (2007) 2.40
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84
Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood (2011) 1.83
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2009) 1.57
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) (2008) 1.38
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Costimulatory molecules as adjuvants for immunotherapy. Front Biosci (2006) 1.37
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther (2006) 1.33
A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int (2005) 1.33
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res (2010) 1.30
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood (2012) 1.30
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant (2013) 1.18
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother (2010) 1.17
Paradigm shifts in cancer vaccine therapy. Exp Biol Med (Maywood) (2008) 1.13
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014) 1.13
Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol (2009) 1.11
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol (2012) 1.09
Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant (2013) 1.07
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol (2007) 1.07
Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther (2009) 1.03
A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer (2006) 1.02
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. J Immunol (2013) 1.01
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther (2010) 0.99
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med (2012) 0.98
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother (2013) 0.98
PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther (2007) 0.97
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother (2011) 0.97
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin Cancer Res (2005) 0.96
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int (2007) 0.95
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2011) 0.94
Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol (2014) 0.94
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol (2009) 0.93
Serum antibodies to blood group A predict survival on PROSTVAC-VF. Clin Cancer Res (2013) 0.92
Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proc Natl Acad Sci U S A (2014) 0.91
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. J Biomed Biotechnol (2010) 0.90
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. Cancer Immunol Immunother (2013) 0.90
Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther (2003) 0.90
The role of angiogenesis inhibitors in prostate cancer. Cancer J (2008) 0.89
Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther (2012) 0.88
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer (2010) 0.88
PSA-based vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2006) 0.88
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunol Immunother (2009) 0.88
The role of soluble CD40L in immunosuppression. Oncoimmunology (2013) 0.88
TRICOM vector based cancer vaccines. Curr Pharm Des (2006) 0.87
Therapeutic vaccines for prostate cancer. Oncologist (2006) 0.86
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J Urol (2010) 0.86
Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci (2010) 0.85
Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol (2014) 0.85
Hepcidin, anaemia, and prostate cancer. BJU Int (2011) 0.85
The use of bisphosphonates in cancer patients. Acta Oncol (2007) 0.85
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. Clin Genitourin Cancer (2007) 0.85
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). Int J Cancer (2007) 0.84
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. Int J Cancer (2013) 0.84
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 0.83
Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. J Natl Compr Canc Netw (2012) 0.83
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer (2004) 0.83
The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer (2010) 0.83
Combining Vaccines with Conventional Therapies for Cancer. Update Cancer Ther (2007) 0.82
Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. Am J Ther (2010) 0.82
Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer. Expert Rev Vaccines (2003) 0.81
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. Oncoimmunology (2012) 0.81
Novel therapeutic strategies in prostate cancer. Cancer Biol Ther (2004) 0.81
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Rev Vaccines (2011) 0.80
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. BJU Int (2006) 0.79
Immunotherapy for prostate cancer: what's the future? Hematol Oncol Clin North Am (2006) 0.79
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. Oncologist (2013) 0.79
Ipilimumab in prostate cancer. Expert Opin Biol Ther (2012) 0.79
Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. Clin Genitourin Cancer (2011) 0.78
Cancer vaccines: current directions and perspectives in prostate cancer. Curr Opin Mol Ther (2009) 0.78
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. Clin Genitourin Cancer (2013) 0.78
A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. J Immunol Methods (2003) 0.77
Therapeutic prostate cancer vaccines: a review of the latest developments. Curr Opin Investig Drugs (2008) 0.77
Therapeutic vaccines for prostate cancer: a review of clinical data. Curr Opin Investig Drugs (2005) 0.77
A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy. Clin Genitourin Cancer (2006) 0.77